Eko Health has received UK regulatory approval for its AI-enabled technology, TRICORDER, to assist clinicians in evaluating heart and lung diseases, aiding in clinical decision-making. Dr. Nicholas Peters leads the team to deploy Eko's technology to 100 GP practices, enhancing heart disease outcomes and reducing healthcare burden through non-invasive cardiac exams. Eko Health CEO Connor Landgraf emphasizes the importance of accurate heart disease detection and its partnership with academic institutions. Eko's AI-enabled technology, integrating a digital stethoscope with electrocardiogram (ECG) data, employs advanced machine learning algorithms to analyze ECG and heart sound data. The TRICORDER program utilizes clinically validated algorithms for detecting reduced left ventricular ejection fraction, structural murmurs indicative of valvular heart disease, and atrial fibrillation, empowering clinicians to make informed decisions for their patients' heart health.